全基因组CRISPR筛选揭示原发渗出性淋巴瘤中cereblon调节剂毒性的遗传介导因子
本研究利用全基因组CRISPR/Cas9正向选择筛选,在3种毒性递增的cereblon调节剂(LEN、POM、CC-122)处理的原发渗出性淋巴瘤(PEL)细胞中鉴定CM毒性效应因子及耐药机制。结果发现赋予耐药性的基因数量随CM效力增强而减少,仅CRBN失活对CC-122完全耐药,UBE2G1失活对LEN和POM耐药,SENP8失活仅对LEN耐药。
要点
- CRBN失活仅对CC-122产生完全耐药。
- UBE2G1失活对LEN和POM产生强耐药。
- SENP8失活通过增加未nedd化CUL4A/B间接限制CRL4CRBN活性,仅对LEN耐药。
核心结论
- 筛选鉴定出CRL4CRBN功能的新参与因子,并定义了PEL中CM耐药的途径。
- 结果为在患者对低效CM复发后增加CM效力提供依据,所鉴定基因可开发为预测PEL及其他癌症中CM效力的生物标志物。
研究设计与样本
- 在PEL中进行正向选择CRISPR筛选,使用3种毒性递增的CM:来那度胺(LEN)、泊马度胺(POM)和CC-122。
主要发现
- 赋予耐药性的基因失活数量随CM效力增强而减少。
- 仅CRBN失活赋予对CC-122的完全耐药。
- E2泛素结合酶UBE2G1失活也对LEN和POM赋予强耐药。
- SENP8失活仅赋予对LEN的耐药,并间接增加未nedd化CUL4A/B水平,以显性负性方式限制CRL4CRBN活性。
- SENP8失活细胞对LEN的敏感性可通过过表达CRBN恢复。
关键数值与推荐
- 使用3种CM:来那度胺(LEN)、泊马度胺(POM)和CC-122,毒性递增。
- 仅CRBN失活对CC-122完全耐药;UBE2G1失活对LEN和POM强耐药;SENP8失活仅对LEN耐药。
- SENP8失活细胞对LEN敏感性可被CRBN过表达恢复。
临床怎么用
- 结果提供依据:在患者对低效CM复发后增加CM效力。
- 所鉴定基因可开发为预测PEL及其他癌症中CM效力的生物标志物。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genome-wide CRISPR/Cas9 screens represent a powerful approach to studying mechanisms of drug action and resistance. Cereblon modulating agents (CMs) have recently emerged as candidates for therapeutic intervention in primary effusion lymphoma (PEL), a highly aggressive cancer caused by Kaposi's sarcoma-associated herpesvirus. CMs bind to cereblon (CRBN), the substrate receptor of the cullin-RING type E3 ubiquitin ligase CRL4CRBN, and thereby trigger the acquisition and proteasomal degradation of neosubstrates. Downstream mechanisms of CM toxicity are incompletely understood, however. To identify novel CM effectors and mechanisms of CM resistance, we performed positive selection CRISPR screens using 3 CMs with increasing toxicity in PEL: lenalidomide (LEN), pomalidomide (POM), and CC-122. Results identified several novel modulators of the activity of CRL4CRBN The number of genes whose inactivation confers resistance decreases with increasing CM efficacy. Only inactivation of CRBN conferred complete resistance to CC-122. Inactivation of the E2 ubiquitin conjugating enzyme UBE2G1 also conferred robust resistance against LEN and POM. Inactivation of additional genes, including the Nedd8-specific protease SENP8, conferred resistance to only LEN. SENP8 inactivation indirectly increased levels of unneddylated CUL4A/B, which limits CRL4CRBN activity in a dominant negative manner. Accordingly, sensitivity of SENP8-inactivated cells to LEN is restored by overexpression of CRBN. In sum, our screens identify several novel players in CRL4CRBN function and define pathways to CM resistance in PEL. These results provide rationale for increasing CM efficacy on patient relapse from a less-efficient CM. Identified genes could finally be developed as biomarkers to predict CM efficacy in PEL and other cancers.
引用
- Patil A, Manzano M, Gottwein E, et al. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. Blood Adv. 2019. PMID: 31300418. doi:10.1182/bloodadvances.2019031732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。